KAYNAKLAR
1. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of The Joint European Soci-ety of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
2. Licka M, Zimmermann R, Zehelein J, et al. Troponin T concent-rations 72 hours after myocardial infarction as a serological es-timate of infarct size. Heart 2002; 87:520-524.
3. Srinivas VS, Cannon CP, Gibson CM, et al. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Am Heart J 2001; 142:29-36.
4. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mor-tality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-1668.
5. The ISIS-2 Investigators. Randomised trial of intravenous strep-tokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-360.
6. Yusuf S. Collins R, MacMahon S, et al. Effect of intravenous nit-rates on mortality in acute myocardial infarction. Lancet 1988;1:1088-1092.
7. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus int-ravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet
2003;361:13-20.
8. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein Ilb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903. 9. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with
or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Gro-up. N Engl J Med 1999;341:1949-1956.
10. GISSI Investigators. Long-term effects of intravenous throm-bolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet 1987;2: 871-874. 11. GUSTO Investigators. An international randomized trial
compa-ring four throm-bolytic strategies for acute myocardial infarcti-on. The GUSTO investigators. N Engl J Med 1993;329:673-682.
12. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
13. The GUSTO III Investigators. A comparison of reteplase with al-teplase for acute myocardial infarction. The Global Use of Stra-tegies to Open Occluded Coronary Arteries (GUSTO III) Investi-gators. N Engl J Med 1997;337:1118-1123.
14. The ASSENT-2 Investigators. Single-bolus tenecteplase compa-red with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-722.
15. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ilb/IIIa in-hibition: the GUSTO V randomised trial. Lancet
2001;357:1905-1914.
16. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated
heparin: the ASSENT-3 randomised trial in acute myocardial in-farction. Lancet 2001;358:605-613.
17. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-ar-tery patency, ventricular function, and survival after acute myo-cardial infarction. N Engl J Med 1993;329: 1615-1622.
18. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized compari-son of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90: 2280-2284. 19. The GISSI Investigators. GISSI-3: effects of lisinopril and
trans-dermal glyceryl trinitrate singly and together on 6-week morta-lity and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Soprawivenza nell’infarto Miocardico. Lancet 1994;343:1115-1122.
20. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intraveno-us magnesium sulphate in 58,050 patients with sintraveno-uspected acu-te myocardial infarction. ISIS-4 (Fourth Inacu-ternational Study of Infarct Survival) Collaborative Group. Lancet 1995;345: 669-685.
21. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con-verting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 145-153. 819. 22. Thiemann D. Primary angioplasty vs thrombolysis in elderly
pa-tients. JAMA 2000;283:601-602.
23. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indicati-ons for fibrinolytic therapy in suspected acute myocardial in-farction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
24. Estess JM, Topol EJ. Fibrinolytic treatment for elderly patients with acute myocardial infarction. Heart 2002;87:308-311. 25. de Boer MJ, Ottervanger JP, van’t Hof AW, et al. Reperfusion
therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thromboly-tic therapy. J Am Coll Cardiol 2002;39:1723-1728.
26. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic the-rapy vs primary percutaneous coronary intervention for myo-cardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002;287:1943-1951.
27. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initi-ated vs hospital-initiPrehospital-initi-ated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211-1216.
28. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A me-ta-analysis. JAMA 2000;283:2692.
29. Gershaw BS, Granger CB, Bunbaum Y, et al. Risk factors, angi-ographic patterns and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO I Investigators. Circulation 2000; 101:27-32.
30. Chatterjee K. Complications of acute myocardial infarction. Curr Probl Cardiol 1993;18:l-79.
31. Giuliana ER, Danielson GK, Pluth JR, et al. Postinfarction ventri-cular septal rupture. Surgical considerations and results. Circu-lation 1974;49:455-459.
32. Fox AC, Glassman E, Isom OW. Surgically remediable compli-cations of myocardial infarction. Prog Cardiovasc Dis 1979; 107:852-855.
50. Menon V, White H, LeJemtel T, et al. The clinical profile of pati-ents with suspected cardiogenic shock due to predominant left ventricular failure. J Am Coll Cardiol 2000;36:1071-1076. 33. Barzilai B, Gessler C, Perez JE, et al. Significance of
Doppler-de-tected mitral regurgitation in acute myocardial infarction. Am J Cardiol 1988;61:220-23.
34. Lehmann KG, Francis CK, Dodge HT, et al. Mitral regurgitation in early myocardial infarction: incidence, clinical detection, and
prognostic implications. TIMI Study Group. Ann Intern Med 1992;117:10-17.
35. Thompson CR, Christopher BE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report for the SHOCK Trial Re-gistry. J Am Coll Cardiol 2000;36;1104-1109.
36. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acutemyocardial infarction—etiologies, manage-ment and outcome: overall findings of the SHOCK Trial Re-gistry. J Am Coll Cardiol 2000;36:1063-1070.
37. Fuchs EM, Heuser RR, Yin FCP, et al. Limitations of pulmonary wedge V waves in diagnosing mitral regurgitation Am J Cardi-ol 1982;49:849-854.
38. Kishon Y, Oh J, Schaff H, et al. Mitral valve operation in postin-farction rupture of a Papillary muscle: immediate results and long term follow-up of 22. patients. Mayo Clin Proc
1992;67:1023-1030.
39. Lopez-Sendon J, Gonzales A, Lopez de Sa E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarc-tion: sensitivity and specificity of clinical, hemodynamic, and echocardiographic criteria. J Am Coll Cardiol 1992;19:1145-1153.
40. Becker R, Charlesworth A, Wilcox R, et al. Cardiac rupture as-sociated with thrombolytic therapy: impact of time to treat-ment in the Late Assesstreat-ment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol 1995;25:1063-1068.
41. Bartunek J, Vanderheyden M, de Bruyne B. Dynamic left ventri-cular outflow tract obstruction after anterior myocardial infarcti-on: a potential mechanism of myocardial rupture. Eur Heart J 1995;16:1439-1442.
42. Killip T, Kimball JT. Treatment of myocardial infarction in a coro-nary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-461.
43. Holmes DR, Bates ER, Kleiman NS, et al, for the GUSTO I inves-tigators. Contemporary reperfusion therapy for cardiogenic
shock: the GUSTO I trial experience J Am Coll Cardiol 1995;26:668-674.
44. Forrester JS, Diamond GA, Chatterjee K. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976;295: 1356-1361.
45. Wong SC, Antonelli T, Sleeper LA, et al. Angiographic findings and clinical correlates in patients with cardiogenic shock comp-licating acute myocardial infarction in the SHOCK Registry. J Am Coll Cardiol 2000;36:1077-1083.
46. Alonso DR, Scheidt S, Post M, et al: Pathophysiology of cardi-ogenic shock: quantification of myocardial necrosis, clinical pathological and electrocardiographic correlation. Circulation 1973;48:588-596.
47. DellTtalia LJ, Lembo NJ, Starling MR, et al. Hemodynamically important right ventricular infarction: follow-up evaluation of right ventricular systolic function at rest and during exercise with radionuclide ventriculography and respiratory gas exchan-ge. Circulation 1987;75:996.
48. Dell’Italia LJ, Starling MR, O’Rourke RA. Physical examination for exclusion of hemodynamically important right ventricular infarction. Ann Intern Med 1983; 99:608-611.
49. Dell’Italia LJ, Starling MR, Crawford MH, et al. Right ventricular infarction: identification by hemodynamic measurements befo-re and after volume loading and corbefo-relation with noninvasive techniques. J Am Coll Cardiol 1984;4:931-939.
50. Dell’Italia LJ, Starling MR. Right ventricular infarction: an impor-tant clinical entity. Curr Probl Cardiol 1984;9:l-58.
51. Dell’Italia LJ, Starling MR, Blumhardt R, et al. Comparative ef-fects of volume loading, dobutamine, and nitroprusside in pati-ents with predominant right ventricular infarction. Circulation 1985;72:1327-1335.
52. Bowers TR. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med 1998;338:933-940.
Cardiol 1982;8: 60-66.
54. Berman J, Haffajee CA, Alpert JS. Therapy of symptomatic peri-carditis after myocardial infarction: retrospective and prospec-tive studies of aspirin, indomethacin, prednisone, and sponta-neous resolution. Am Heart J 1981; 101: 750-753.
55. Antithrombotic Therapy forCoronary Artery Disease, The Se-venth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126: 513S-548S.
56. ACC/AHA-Guidlines of Patients with ST-Elevation Myocardial ‹nfarction. Circulation 2004;110:588-636.
57. AHA-National Cholesterol Education Program(NCEP)-III. Circula-tion 2003;24:26-66.
58. ESC-Guidlines of ST-elevation Acute Miyocardial ‹nfarction. Eu-ropean Heart J 2003;24:26-66.